The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Submission based on results from pivotal phase III trial showing all primary endpoints met
Application based on results from the TROPION-Breast01 Phase III trial
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Subscribe To Our Newsletter & Stay Updated
